Latest advances on the maintenance therapy of multiple myeloma / 中国实验血液学杂志
Journal of Experimental Hematology
;
(6): 250-254, 2015.
Article
Dans Chinois
| WPRIM
| ID: wpr-259605
ABSTRACT
Multiple myeloma (MM) is an uncurable disease. Chemotherapy with standard dose or autologous stem cell transplantation (auto-HSCT) after chemotherapy with high dose is able to induce remission, but relapse still exists. For this reason the ultimate goal of MM treatment is to improve relapse free survival (RFS) and progression free survival (PFS) efficiently. Recently, maintenance therapy made substantial progress in improving progression-free survival and overall survival (OS) of patients with multiple myeloma, especially thalidomide, lenalidomide and bortezomib used in clinic. Here, the latest advances of clinical researches on maintenance therapy of MM are summarized briefly in this review.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Pyrazines
/
Thalidomide
/
Acides boroniques
/
Transplantation de cellules souches hématopoïétiques
/
Survie sans rechute
/
Bortézomib
/
Myélome multiple
Limites du sujet:
Humains
langue:
Chinois
Texte intégral:
Journal of Experimental Hematology
Année:
2015
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS